Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 19:8:293-298.
doi: 10.5414/ALX02522E. eCollection 2024.

Basophil activation test in Hymenoptera venom allergy

Bernadette Eberlein  1 , Knut Brockow  1 , Ulf Darsow  1 , Tilo Biedermann  1 , Simon Blank  2
Affiliations
Review

Basophil activation test in Hymenoptera venom allergy

Bernadette Eberlein et al. Allergol Select. .

Abstract

Before starting venom-specific immunotherapy (VIT), systemic sting reactions to Hymenoptera venoms require allergological workup in order to prove an IgE-mediated reaction and to identify the culprit insect venom. In addition to skin tests and the determination of specific IgE antibodies, the basophil activation test (BAT) using flow cytometry has emerged as a powerful tool and sensitive marker for this purpose in recent years. BAT seems to have a better informative value in terms of clinical relevance compared to the other tests. In Hymenoptera venom allergies, BAT is particularly useful for the diagnosis of cases with unclear or contradictory history and sensitization profile. Its results are associated with adverse reactions during VIT and efficacy of VIT and therefore have a certain predictive value for side effects and treatment failure of VIT. In research, it is mainly used to characterize the allergenic components of Hymenoptera venoms. This review article focuses on these topics.

Keywords: Hymenoptera venom allergy; basophil activation test; component resolved diagnosis; venom immunotherapy.

PubMed Disclaimer

Conflict of interest statement

BE reports non-financial support from Bühlmann Laboratories outside the submitted work. KB received lecture fees from ALK, Bencard and ThermoFisher and reports non-financial support from Bühlmann Laboratories outside the submitted work. SB reports grants and personal fees from Bencard, Thermo Fisher Scientific and Allergy Therapeutics, grants from Leti Pharma, and non-financial support from Siemens Healthineers, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Table 1. Overview of possible current applications of basophil activation test for Hymenoptera venom allergy. Field of applicationGroup of patientsAllergens to be used in the BATDiagnosis of Hymenoptera venom allergyPatients with negative results in routine testingWhole venom extracts, allergen componentsPatients with double sensitizationWhole venom extracts, allergen components Efficacy and tolerance of VITPatients with adverse events during VITSubmaximal concentrations of whole venom extracts in the course of VITPatients with systemic reactions after a field sting or sting challenge during VITSubmaximal concentrations of whole venom extracts in the course of VIT Characterization of allergen componentsPatients with a history or sensitization profile relevant to the scientific issueAllergen components BAT = basophil activation test; VIT = venom-specific immunotherapy.

References

    1. Ruëff F Bauer A Becker S Brehler R Brockow K Chaker AM Darsow U Fischer J Fuchs T Gerstlauer M Gernert S Hamelmann E Hötzenecker W Klimek L Lange L Merk H Mülleneisen NK Neustädter I Pfützner W Sieber W Diagnosis and treatment of Hymenoptera venom allergy: S2k Guideline of the German Society of Allergology and Clinical Immunology (DGAKI) in collaboration with the Arbeitsgemeinschaft für Berufs- und Umweltdermatologie e.V. (ABD), the Medical Association of German Allergologists (AeDA), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNOKC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Allergy and Environmental Medicine (GPA), German Respiratory Society (DGP), and the Austrian Society for Allergy and Immunology (ÖGAI). Allergol Select. 2023; 7: 154–190. - PMC - PubMed
    1. Eberlein B Basophil activation as marker of clinically relevant allergy and therapy outcome. Front Immunol. 2020; 11: 1815. - PMC - PubMed
    1. Hoffmann HJ Santos AF Mayorga C Nopp A Eberlein B Ferrer M Rouzaire P Ebo DG Sabato V Sanz ML Pecaric-Petkovic T Patil SU Hausmann OV Shreffler WG Korosec P Knol EF The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy. 2015; 70: 1393–1405. - PubMed
    1. Eberlein-König B Schmidt-Leidescher C Rakoski J Behrendt H Ring J In vitro basophil activation using CD63 expression in patients with bee and wasp venom allergy. J Investig Allergol Clin Immunol. 2006; 16: 5–10. - PubMed
    1. Korosec P Erzen R Silar M Bajrovic N Kopac P Kosnik M Basophil responsiveness in patients with insect sting allergies and negative venom-specific immunoglobulin E and skin prick test results. Clin Exp Allergy. 2009; 39: 1730–1737. - PubMed

LinkOut - more resources